Resveratrol for Insulin-Like Growth Factor
Resveratrol does not reliably alter IGF-1 in humans and may blunt training adaptation.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Not recommended for this purpose
- Expected timeframe
- Not established
Protocol
- form
- Trans-resveratrol
- duration
- Trials ran 4 weeks to 12 months
- co factor
- Evidence is insufficient. A small number of human trials have measured IGF-1 as a secondary outcome with inconsistent results - one study in healthy older adults reported reduced IGF-1 and IGFBP-3 at high dose, others found no change. The interpretation is also contested: lower IGF-1 is associated with longevity in model organisms and in Laron syndrome, where growth hormone receptor deficiency confers apparent protection from cancer and diabetes, but low IGF-1 in older adults is associated with frailty, sarcopenia, reduced bone density and increased cardiovascular mortality in observational data. The relationship is U-shaped, so lowering IGF-1 is not straightforwardly desirable.
- titration
- Not applicable - no dose-response for IGF-1 has been established
- starting dose
- Not established. Human trials used 150-1,000 mg/day
Evidence
What the studies say
No studies are yet linked to both Resveratrol and Insulin-Like Growth Factor.
Safety
Caveats
Avoid alongside a structured training block.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.